Lymphoma & Leukemia Program
About Lymphoma and Leukemia
Since lymphoma is a cancer of the immune system, a major scientific goal of the Lymphoma and Leukemia Program is to use knowledge gained from immunology to understand and treat lymphoid malignancies. This goal is being accomplished by gaining better understanding of the biology underlying lymphoid and myeloid neoplasms and applying this knowledge to improve the diagnosis and treatment of these disorders.
Program Aims:
- Discover the Genetic and Cellular Origins of Lymphomas and Leukemias
- Develop Novel Methods of Diagnosis and Biomarker Monitoring of these Diseases
- Develop New Therapies
Program Directors
Program Directory
Lymphoma and Leukemia Clinical Trials
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Stanford is currently accepting patients for this trial. -
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Stanford is currently accepting patients for this trial. -
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Stanford is currently accepting patients for this trial. -
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Stanford is currently accepting patients for this trial.